The Human Endocrine Pancreas: New Insights on Replacement and Regeneration

Juan Dominguez-Bendala, Giacomo Lanzoni, Dagmar Klein, Silvia Álvarez-Cubela, Ricardo Pastori

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Islet transplantation is an effective cell therapy for type 1 diabetes (T1D) but its clinical application is limited due to shortage of donors. After a decade-long period of exploration of potential alternative cell sources, the field has only recently zeroed in on two of them as the most likely to replace islets. These are pluripotent stem cells (PSCs) (through directed differentiation) and pancreatic non-endocrine cells (through directed differentiation or reprogramming). Here we review progress in both areas, including the initiation of Phase I/II clinical trials using human embryonic stem cell (hESc)-derived progenitors, advances in hESc differentiation in vitro, novel insights on the developmental plasticity of the pancreas, and groundbreaking new approaches to induce β cell conversion from the non-endocrine compartment without genetic manipulation.

Original languageEnglish (US)
Pages (from-to)153-162
Number of pages10
JournalTrends in Endocrinology and Metabolism
Volume27
Issue number3
DOIs
StatePublished - Mar 1 2016

    Fingerprint

Keywords

  • Diabetes
  • Human embryonic stem cells
  • Islets
  • Pancreatic regeneration
  • β cells

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this